T1	Participants 536 639	Adult and pediatric patients with allergic rhinoconjunctivitis and/or asthma were included in the study
T2	Participants 641 672	Ten subjects served as controls
T3	Participants 710 773	Forty-three subjects were allocated to sublingual immunotherapy
T4	Participants 1354 1389	patients with respiratory allergies
